Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Research and Practice in Thrombosis and Haemostasis ; 5(SUPPL 2), 2021.
Article in English | EMBASE | ID: covidwho-1509096

ABSTRACT

Background : COVID-19 frequently associated thrombotic complication that could determine severe evolution. Inflammation was proved as important pathogenic mechanism of thrombosis. Aims : The main objective was to evaluate the role of inflammation in increased risk of thrombosis in COVID 19 patients. Methods : Our study was prospective and included all patients diagnosed with COVID 19 between April-September 2020 in Hematology, Pneumology and Intensive Care Unit from Colentina Clinical Hospital (285 patients). The diagnosis was established using molecular test for SARS-Cov2. Results : Thrombotic complication was presented in 56 COVID-19 patients (19, 65%), The higher incidence of thrombosis was observed in severe form of COVID-19: stage 3 (66%) and stage 2 (26.3%), Comorbidities: diabetes mellitus, obesity and arterial hypertension were presented in majority of COVID 19 patients with thrombosis. Acute thrombosis (stroke, myocardial infarction or pulmonary embolism) was diagnosed in 14 patients;all of them were admitted in Intensive care unit due severe form of COVID-19. Inflammatory markers including C reactive protein (CRP), procalcitonin, ferritin are significantly increased in COVID-19 group with acute thrombosis compared with COVID -19 patients with thrombosis in medical history CRP 148.86 mg/L (2.96-386.5) vs. 58.24 mg/L (min 0.25, max 212.98) P = 0.005;procalcitonin 0.93 ng/ml (0.04-784) vs 0.18 (min 0.02, max 14.1) P = 0.02;ferritin 702 ng/ml (min 102, max 4070) vs. 1195 ng/ml (min 358, max 12800) P = 0.03. There is no significant difference between haematological parameters in COVID-19 patients with acute thrombosis or in their medical history. D Dimers are significant increased in patients with acute thrombosis 4.79 ug/ml (0.51-20) vs patients with medical history of thrombosis 2.12 (0.31-20), P = 0.02. The level of protein C, protein S and antitrombine III, antiphospholipid antibodies are not significant modified in the both groups. Conclusions : The assessment of inflammation parameters are very important in COVID-19 patients especially those with a history of thrombosis or who have significant comorbidities (diabetes mellitus, arterial hypertension or obesity).

2.
Revista Romana De Medicina De Laborator ; 29(4):377-385, 2021.
Article in English | Web of Science | ID: covidwho-1496908

ABSTRACT

Introduciton: COVID19 is one of the largest pandemics. Since December 2019 until now the coronavirus has infected over 131 million people. The mortality rate in the general population varies between 1 to 5%, with a potential of over 30% in patients with neoplasms. Methods: The main objective of the study was to identify some peculiarities of the evolution, complications and treatment of patients with acute leukaemia and COVID-19. The study was retrospective and included 50 patients with acute leukaemia and COVID-19. Results: Recent administration of chemotherapy was identified in 20 patients with acute myeloblastic leukaemia and 4 patients with acute lymphoblastic leukaemia. The newly diagnosed patients or those undergoing intensive chemotherapy, in particular elderly patients, had a severe form of COVID-19 and an unfavourable evolution, and these clinical situations were identified as predictive factors for adverse outcomes. Patients with acute lymphoblastic leukaemia had a shorter survival curve compared to patients with acute myeloblastic leukaemia. Pneumonia was present especially in patients with acute myeloblastic leukaemia, most patients having over 30% of lung fields affected (55.26%). Patients with an unfavourable outcome had significantly increased median values of C-reactive protein, procalcitonin and interleukin6. Conclusions: Patients with acute leukaemia, especially acute myeloblastic leukaemia who have been diagnosed with COVID-19 infection require special attention because they may associate complications and adverse outcomes of COVID-19. The results we obtained require evaluation in a larger group of patients and analysis in the follow-up period after COVID-19.

3.
Roeker, L. E.; Scarfo, L.; Chatzikonstantinou, T.; Abrisqueta, P.; Eyre, T. A.; Cordoba, R.; Prat, A. M.; Villacampa, G.; Leslie, L. A.; Koropsak, M.; Quaresmini, G.; Allan, J. N.; Furman, R. R.; Bhavsar, E. B.; Pagel, J. M.; Hernandez-Rivas, J. A.; Patel, K.; Motta, M.; Bailey, N.; Miras, F.; Lamanna, N.; Alonso, R.; Osorio-Prendes, S.; Vitale, C.; Kamdar, M.; Baltasar, P.; Osterborg, A.; Hanson, L.; Baile, M.; Rodriguez-Hernandez, I.; Valenciano, S.; Popov, V. M.; Garcia, A. B.; Alfayate, A.; Oliveira, A. C.; Eichhorst, B.; Quaglia, F. M.; Reda, G.; Jimenez, J. L.; Varettoni, M.; Marchetti, M.; Romero, P.; Grau, R. R.; Munir, T.; Zabalza, A.; Janssens, A.; Niemann, C. U.; Perini, G. F.; Delgado, J.; San Segundo, L. Y.; Roncero, M. I. G.; Wilson, M.; Patten, P.; Marasca, R.; Iyengar, S.; Seddon, A.; Torres, A.; Ferrari, A.; Cuellar-Garcia, C.; Wojenski, D.; El-Sharkawi, D.; Itchaki, G.; Parry, H.; Mateos-Mazon, J. J.; Martinez-Calle, N.; Ma, S.; Naya, D.; Van der Spek, E.; Seymour, E. K.; Vazquez, E. G.; Rigolin, G. M.; Mauro, F. R.; Walter, H. S.; Labrador, J.; De Paoli, L.; Laurenti, L.; Ruiz, E.; Levin, M. D.; Simkovic, M.; Spacek, M.; Andreu, R.; Walewska, R.; Perez-Gonzalez, S.; Sundaram, S.; Wiestner, A.; Cuesta, A.; Broom, A.; Kater, A. P.; Muina, B.; Velasquez, C. A.; Ujjani, C. S.; Seri, C.; Antic, D.; Bron, D.; Vandenberghe, E.; Chong, E. A.; Lista, E.; Garcia, F. C.; Del Poeta, G.; Ahn, I.; Pu, J. J.; Brown, J. R.; Campos, J. A. S.; Malerba, L.; Trentin, L.; Orsucci, L.; Farina, L.; Villalon, L.; Vidal, M. J.; Sanchez, M. J.; Terol, M. J.; De Paolis, M. R.; Gentile, M.; Davids, M. S.; Shadman, M.; Yassin, M. A.; Foglietta, M.; Jaksic, O.; Sportoletti, P.; Barr, P. M.; Ramos, R.; Santiago, R.; Ruchlemer, R.; Kersting, S.; Huntington, S. F.; Herold, T.; Herishanu, Y.; Thompson, M. C.; Lebowitz, S.; Ryan, C.; Jacobs, R. W.; Portell, C. A.; Isaac, K.; Rambaldi, A.; Nabhan, C.; Brander, D. M.; Montserrat, E.; Rossi, G.; Garcia-Marco, J. A.; Coscia, M.; Malakhov, N.; Fernandez-Escalada, N.; Skanland, S. S.; Coombs, C. C.; Ghione, P.; Schuster, S. J.; Foa, R.; Cuneo, A.; Bosch, F.; Stamatopoulos, K.; Ghia, P.; Mato, A. R.; Patel, M..
Blood ; 136:14, 2020.
Article in English | Web of Science | ID: covidwho-1088505
SELECTION OF CITATIONS
SEARCH DETAIL